Subscribe to our Newsletters !!
How are viruses different from bacteria apex ? O
Pharmaceutical laboratories have been adopting imm
Generally, a debate about Isopure protein and regu
Alembic Pharmaceuticals Limited appoints Mr. Manis
The importance of comparing the treatment of asthm
It is important to understand that natural remedie
In a world constantly in motion, Microbioz India r
It was an event of American Academy of Allergy, Asthma and Immunology (AAAAI) 2016 Annual Meeting in Los Angeles, Researcher reported an injectable antibiotic drug “Omalizumab” decreases cold in children having asthma, and Omalizumab is an injectable drug generally used to treat asthma when normal corticosteroids inhaled drug not works sold under brand name Xolair.
These findings are the result of Preventative Omalizumab or Step-up Therapy for Severe Fall Exacerbations (PROSE) the study under regulations of Inner-City Asthma Consortium (ICAC).
Inner-City asthma Consortium (ICAC) is supported by National Institute of Allergy and Infectious Diseases (NIAID) and is type of asthma program.
Under this study researcher trials over 478 asthma children residing in city throughout United States, and gave three types of treatment in normal cold season when attack of asthma is worsen.
Out of three treatments one is control one and gave normal asthma treatment guidelines, and another two is given either fluticasone or Omalizumab, fluticasone is an inhaled corticosteroid drug sold under brand name Floven. At the result researcher seen that the children having treatment with fluticasone or Omalizumab decrease cold by 27 % in compare with treatment of standard asthma guidelines.
Note: The above story is for information purposes only for more information go through original story source.
Story Source: NIH/National Institute of Allergy and Infectious Diseases
